Matrix metalloproteinase inhibition of pancreatic cancer: Matching mechanism of action to clinical trial design

Journal of Clinical Oncology

Volumn 19, Issue 15, 2001, Pages 3445-3446

  Hess, K R ^a   Abbruzzese, J L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; GELATINASE A; GELATINASE B; GEMCITABINE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PROTEINASE; STROMELYSIN; TANOMASTAT;

CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 0035425424     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.15.3445     Document Type: Editorial

References (15)

1. Marimistat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
2. Current approaches and future strategies for systemic therapy of pancreatic carcinoma
3. Changing views of the role of matrix metalloproteinases in metastasis
4. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
5. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
6. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer
7. Regulation of matrix metalloproteinase gene expression
8. Effective adenoviral transfer of IkappaBalpha into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-kappaB dependent
9. Cooperation between transcription factor AP-1 and NF-κB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia
10. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
11. Development of matrix metalloproteinase inhibitors in cancer therapy
12. Matrix metalloproteinase inhibition improves survival in an orthotopic model of human Pancreatic Cancer
13. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
14. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced pancreatic cancer
15. A randomized double-blind placebo-controlled study of marimistat in patients with inoperable gastric adenocarcinoma